|
|
|
| home > white papers > Overcoming research challenges with Adaptive Trials - PCI Pharma Services |
|
|
 WHITE PAPERS |
|
PCI Pharma Services
|
|
Overcoming research challenges with Adaptive Trials
|
|
There has been cause for concern within the pharmaceutical industry over
the last five years, regarding increasing research and development
costs, combined with a fall in the number of new drugs brought to
market. In an attempt to overcome this issue there has been a
significant rise in the use of adaptive clinical trial designs, whilst
saving time and money as well as facilitating more effective decision
making. One of the biggest challenges that pharmaceutical companies have
experienced has been delivering compliant clinical trials supplies
across diverse patient populations in the relatively short timeframes
that adaptive trial designs require, remaining focused on ensuring that
patient compliance and product quality is in no way compromised. This
demand has led to the launch of fast response services that support
Research and Development in responding to changing dosing regimens
mid-trial.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
MyMD Pharmaceuticals Inc., a clinical stage
pharmaceutical company committed to extending healthy lifespan by
focusing on developing two therapeutic platforms, today announced that
the United States Patent and Trademark Office (USPTO) has issued U.S.
Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the
Treatment of Substance Addiction and Other Disorders.”
More info >> |
|
 |
White Papers |
 |
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
RSSL
Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >> |
|
|
|
